




FUNDACIÓN
RAMÓN ARECES



Cima
Universidad
de Navarra



Clínica
Universidad
de Navarra



International Symposium / Simposio internacional

“Translational and reverse-translational research in cancer immunotherapy”

“Investigación del laboratorio al paciente y del paciente al laboratorio en inmunoterapia del cáncer”

Coordinator / Coordinador

Ignacio Melero. CUN and CIMA. Universidad de Navarra

Organizing Committee / Comité Organizador

Ignacio Melero, Pedro Berraondo, María Rodríguez Ruiz, Álvaro Teijeira y Miguel Fernández de Sanmamed

Scientific collaborators / Colaboradores científicos

Aina Segué, Assunta Cirella, Claudia Augusta Di Trani, Natasa Vukovic, Shuyu Huang

Date / Fecha

29-30 September 2022 / 29 -30 de septiembre 2022

Venue / Sede

Fundación Areces

C/ Vitruvio, 5. 28006 Madrid. Spain

Web

<https://cancerimmunotherapyday-cun.com/>

SCIENTIFIC PROGRAM / PROGRAMA CIENTÍFICO

29 September (Thursday)

08.30 - 09.00. Registrations

09.00 - 09.15 Welcome

Raimundo Pérez-Hernández y Torra, Mariano Barbacid e Ignacio Melero

09.15 - 11.30 Keynote lectures

Chairs: Estela Paz. Hospital 12 de Octubre and Miguel Fernández de Sanmamed. CIMA y CUN. Spain

09.15 - 09.50 Intravital imaging of immunotherapy

Philippe Bousso. Institut Pasteur. France

09.50 - 10.00 Q&A

10.00 - 10.35 Immunotherapy for ovarian cancer

George Coukos. University of Lausanne. Switzerland

10.35 - 10.45 Q&A

10.45 - 11.20 HLA Class-I loss and cancer immune escape

Federico Garrido. University of Granada. Spain

11.20 - 11.30 Q&A

11.30 - 12.00 BREAK

12.00 - 13.45 SESSION 1

Chair: Juan José Lasarte. CIMA. Spain

12.00 - 12.30 Novel mechanisms of immune escape in HCC

Amaia Lujambio. Icahn School of Medicine at Mount Sinai. USA

12.30 - 13.00 Natural conventional Dendritic cells and their metabolism in cancer immunotherapy

David Sancho. CNIC. Spain

13.00 - 13.30 CD137 (4-1BB)-based immunotherapy: 25th anniversary

Ignacio Melero. CIMA y CUN. Spain

13.30 - 13.45 Q&A

13.45 - 15.30 LUNCH

15.30 - 17.15 SESSION 2

Chair: Sandra Hervás. CIMA. Spain

15:30 - 16.00 Adoptive T cell therapy in melanoma management

Inge Marie Svane. Center for Cancer Immune Therapy (CCIT). Denmark

16.00 - 16.30 Innovation in the CAR T cell arena

Sònia Guedan. Hospital Clinic Barcelona. Spain

16.30 - 17.00 Adoptive T cell therapy based on neoantigens

Sthephanie Goff. National Cancer Institute. USA

17.00 - 17.15 Q&A

17.15 - 17.50 Keynote lecture (sponsored by Highlight Therapeutics)

Chair: Marisol Quintero. Highlight Therapeutics. Spain

Deciphering the mechanisms of cancer immunotherapy

Ira Mellman. Genentech. USA

17.50 - 18.00 Q&A

18.00 - 18.35 SESSION 3

Chair: Tim Elliott. University of Oxford. UK

18.00 - 18.30 Neoadjuvant approaches in cancer immunotherapy

Christian Blank. Netherlands Cancer Institute. The Netherlands

18.30 -18.35 Q&A

30 September (Friday)

9.00 - 10.30 Keynote lectures

Chair: Pedro Berraondo. CIMA. Spain

9.00 - 9.35 The IL-1 family in cancer inflammation

Alberto Mantovani. Humanitas University. Italy

9.35 - 9.45 Q&A

9.45 - 10.20 Exploitation of cancer neoantigens

Beatriz Carreño. University of Pennsylvania School of Medicine. USA

10.20 - 10.30 Q&A

10.30 - 11.00 BREAK

11.00 - 12.45 SESSION 4

Chair: Christian Blank. Netherlands Cancer Institute. The Netherlands

11.00 - 11.30 Towards clinical development of radioimmunotherapy strategies

María Rodríguez Ruiz. CUN. Spain

11.30 - 12.00 Heterogeneity of immune biomarkers in NSCLC

Crispin Halley. UCL. UK

12.00 - 12.30 Combining radiotherapy and immunotherapy

Tim Ilidge. Cancer Research UK Manchester Institute. UK

12.30 - 12.45 Q&A

12.45 - 13.50 SESSION 5

Chair: Ignacio Melero. CIMA y CUN. Spain

12.45 - 13.15 Immunotherapy of hepatocellular carcinoma

Bruno Sangro. CUN. Spain

13.15 - 13.45 NASH and hepatocellular carcinoma-immunotherapy

Mathias Heikenwälder. German Cancer Research Center. Germany

13.45 - 13.55 Q&A

13.55 - 16.00 LUNCH

16.00 - 17.45 SESSION 6

Chair: Fernando Pastor. CIMA. Spain

16.00 - 16.30 Dissecting and modulating anti-cancer immunity in patient-derived tumor fragments

Daniela Thommen. Netherlands Cancer Institute. The Netherlands

16.30 - 17.00 LIF in cancer immunology and immunotherapy

Joan Seoane. VHIO. Spain

17.00 - 17.30 TGF β in colon cancer immunology

Eduard Batlle. IRB Barcelona. Spain

17.30 -17.45 Q&A

ADJOURN

Event sponsored by:



BIOLINE[®] RX



HIGHLIGHT
THERAPEUTICS